KENILWORTH, N.J. and
WOODCLIFF LAKE, N.J., Dec. 12, 2016 /PRNewswire/ -- Merck (NYSE:
MRK), known as MSD outside the United
States and Canada, and
Eisai Inc. today announced new interim data investigating Merck's
anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in
combination with Eisai's microtubule dynamics inhibitor,
HALAVEN® (eribulin) in patients with metastatic
triple-negative breast cancer (TNBC). Findings presented during the
2016 San Antonio Breast Cancer Symposium (SABCS) were based on
interim data from 39 evaluable patients and showed an overall
response rate (ORR) of 33.3% (n=13/39; 95% CI, 19.5-48.1), with one
complete response and 12 partial responses (Abstract #: P5-15-02).
ORR was similar between PD-L1-positive and -negative cohorts [PD-L1
positive=29.4% (n=5/17; 95% CI, 11.1-51.1); PD-L1 negative=33.3%
(n=6/18; 95% CI, 14.1-54.6)]. HALAVEN and KEYTRUDA are not approved
for use in combination.
The most common treatment-emergent adverse events (incidence
greater than or equal to 35%) for the combination regimen were
fatigue (n=29; 74.4%), nausea (n=20; 51.3%), peripheral neuropathy
(n=17; 43.6%), neutropenia (n=15; 38.5%), and alopecia (n=14;
35.9%), with grade 3 or higher treatment-emergent adverse events
observed in 66.7% (n=26) of patients. The two most common grade 3
or higher treatment-emergent adverse events observed were
neutropenia (n=12; 30.8%) and fatigue (n=3; 7.7%). The possible
immune-mediated adverse events of clinical interest with KEYTRUDA
(grade 3/4) included rash (n=2; 5.1%), pneumonitis (n=1; 2.6%),
hyperglycemia (n=1; 2.6%), renal failure (n=1; 2.6%) and rash
generalized (n=1; 2.6%). Events of clinical interest for HALAVEN
(grade 3/4) included neutropenia (n=11, 28.2%), febrile neutropenia
(n=1; 2.6%), and peripheral neuropathy (n=1; 2.6%). There were 10
discontinuations due to treatment-emergent adverse events and no
treatment-related deaths.
"Little progress has been made in metastatic triple-negative
breast cancer, which is an aggressive and difficult-to-treat
cancer. This initial evaluation of the combination of KEYTRUDA and
HALAVEN is encouraging and represents an important part of our
multi-pronged effort to bring forward new potential approaches for
patients with this type of cancer," said Roger Dansey, MD, senior vice president and
therapeutic area head, oncology late-stage development, Merck
Research Laboratories.
"Patients with metastatic triple-negative breast cancer have a
limited number of treatment options, making clinical study of new
potential therapeutic approaches essential," said Alton Kremer, MD, PhD, chief clinical officer
and chief medical officer, Oncology Business Group at Eisai. "With
this ongoing study, we hope to learn more about the potential of
HALAVEN as part of a combination regimen with KEYTRUDA, with the
long-term goal of addressing the unmet medical needs of patients
with metastatic triple-negative breast cancer."
"In addition to anti-mitotic effects, in preclinical and
translational studies, eribulin induced tumor vascular remodeling,
reduction of hypoxia and promotion of the less aggressive
epithelial phenotype in advanced breast cancer tumor tissue. We
look forward to further understanding how these effects of eribulin
on tumor biology and microenvironment may impact the effect of
pembrolizumab on the immune system's T cells," said Sara Tolaney, MD, MPH, medical oncologist,
Dana-Farber Cancer Institute, Boston, and the principal investigator of the
study.
HALAVEN (eribulin mesylate) Injection is approved by the U.S.
Food and Drug Administration (FDA) for the treatment of patients
with metastatic breast cancer who have previously received at least
two chemotherapeutic regimens for the treatment of metastatic
disease. Prior therapy should have included an anthracycline and a
taxane in either the adjuvant or metastatic setting. KEYTRUDA is
not indicated in any type of breast cancer. This release discusses
investigational uses for FDA-approved products. This release is not
intended to convey conclusions about efficacy or safety. There is
no guarantee that any investigational uses of such FDA-approved
products will successfully complete clinical development or gain
FDA approval.
About the Study
The single-arm, multi-center phase 1b/2 study
(ClinicalTrials.gov Identifier: NCT02513472) is investigating the
combination of KEYTRUDA (pembrolizumab) (200 mg intravenously on
Day 1) with HALAVEN (eribulin mesylate) Injection (1.4
mg/m2 intravenously on Day 1 and Day 8) in 21-day cycles
in 95 patients with metastatic TNBC who had previously been treated
with up to two lines of chemotherapy. The primary endpoint of the
phase 1b portion of the study is to assess the safety and
tolerability of the combination; for the phase 2 portion of the
study, the primary endpoint is investigator-assessed ORR and
secondary endpoints include progression-free survival, overall
survival and duration of response as well as efficacy in a subset
of patients with PD-L1-positive tumors.
The results presented at SABCS were based on a planned interim
analysis. At the time of data cutoff (July
12, 2016), 89 patients were enrolled, 39 of whom were
evaluable.
The study is being conducted under an existing clinical trial
collaboration agreement between the two companies.
About Breast Cancer
Breast cancer is a malignant tumor that begins in the cells of
the breast. In 2016, an estimated 246,660 women will be diagnosed
with breast cancer in the United
States, and nearly 40,450 women will die from the
disease.
Triple-negative breast cancer is an aggressive type of breast
cancer where the cancer cells do not have estrogen or progesterone
receptors and do not have HER2, a growth-promoting protein.
Approximately 12% of breast cancer patients are diagnosed with
triple-negative breast cancer. Triple-negative breast cancer tends
to grow and spread quickly. Specifically, patients with
triple-negative breast cancer are nearly two times more likely to
have distant metastatic disease than those with most other types of
breast cancer.
Metastatic breast cancer is an advanced stage of the disease
that occurs when cancer spreads beyond the breast to other parts of
the body. It is estimated that approximately five percent to 10
percent of women with breast cancer will have metastatic disease at
the time of diagnosis. Of these women, an estimated one in five is
expected to survive five years.
About KEYTRUDA® (pembrolizumab)
KEYTRUDA is a humanized monoclonal antibody that works by
increasing the ability of the body's immune system to help detect
and fight tumor cells. KEYTRUDA blocks the interaction between PD-1
and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes
which may affect both tumor cells and healthy cells.
KEYTRUDA (pembrolizumab) is administered as an intravenous
infusion over 30 minutes every three weeks for the approved
indications. KEYTRUDA for injection is supplied in a 100 mg single
use vial.
KEYTRUDA Indications and Dosing
Melanoma
KEYTRUDA is indicated for the treatment of patients with
unresectable or metastatic melanoma at a dose of 2 mg/kg every
three weeks until disease progression or unacceptable toxicity.
Lung Cancer
KEYTRUDA is indicated for the first-line treatment of patients
with metastatic non-small cell lung cancer (NSCLC) whose tumors
have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as
determined by an FDA-approved test, with no EGFR or ALK genomic
tumor aberrations.
KEYTRUDA is also indicated for the treatment of patients with
metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined
by an FDA-approved test, with disease progression on or after
platinum-containing chemotherapy. Patients with EGFR or ALK genomic
tumor aberrations should have disease progression on FDA-approved
therapy for these aberrations prior to receiving KEYTRUDA.
In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of
200 mg every three weeks until disease progression, unacceptable
toxicity, or up to 24 months in patients without disease
progression.
Head and Neck Cancer
KEYTRUDA is indicated for the treatment of patients with
recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC) with disease progression on or after platinum-containing
chemotherapy. This indication is approved under accelerated
approval based on tumor response rate and durability of response.
Continued approval for this indication may be contingent upon
verification and description of clinical benefit in the
confirmatory trials. In HNSCC, KEYTRUDA is administered at a
fixed dose of 200 mg every three weeks until disease progression,
unacceptable toxicity, or up to 24 months in patients without
disease progression.
Selected Important Safety Information for
KEYTRUDA® (pembrolizumab)
KEYTRUDA can cause immune-mediated pneumonitis, including fatal
cases. Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving
KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%),
and 5 (0.1%) pneumonitis, and occurred more frequently in patients
with a history of prior thoracic radiation (6.9%) compared to those
without (2.9%). Monitor patients for signs and symptoms of
pneumonitis. Evaluate suspected pneumonitis with radiographic
imaging. Administer corticosteroids for Grade 2 or greater
pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue
KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.
KEYTRUDA can cause immune-mediated colitis. Colitis occurred in
48 (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.4%), 3 (1.1%), and 4 (<0.1%) colitis. Monitor patients for
signs and symptoms of colitis. Administer corticosteroids for Grade
2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3;
permanently discontinue KEYTRUDA for Grade 4 colitis.
KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred
in 19 (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.1%), 3 (0.4%), and 4 (<0.1%) hepatitis. Monitor patients for
changes in liver function. Administer corticosteroids for Grade 2
or greater hepatitis and, based on severity of liver enzyme
elevations, withhold or discontinue KEYTRUDA.
KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17
(0.6%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.2%), 3 (0.3%), and 4 (<0.1%) hypophysitis. Monitor patients
for signs and symptoms of hypophysitis (including hypopituitarism
and adrenal insufficiency). Administer corticosteroids and hormone
replacement as clinically indicated. Withhold KEYTRUDA for Grade 2;
withhold or discontinue for Grade 3 or 4 hypophysitis.
KEYTRUDA can cause thyroid disorders, including hyperthyroidism,
hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96
(3.4%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.8%) and 3 (0.1%) hyperthyroidism. Hypothyroidism occurred in 237
(8.5%) of 2799 patients receiving KEYTRUDA, including Grade 2
(6.2%) and 3 (0.1%) hypothyroidism. The incidence of new or
worsening hypothyroidism was higher in patients with HNSCC
occurring in 28 (15%) of 192 patients with HNSCC, including Grade 3
(0.5%) hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799
patients receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis.
Monitor patients for changes in thyroid function (at the start of
treatment, periodically during treatment, and as indicated based on
clinical evaluation) and for clinical signs and symptoms of thyroid
disorders. Administer replacement hormones for hypothyroidism
and manage hyperthyroidism with thionamides and beta-blockers as
appropriate. Withhold or discontinue KEYTRUDA (pembrolizumab) for
Grade 3 or 4 hyperthyroidism.
KEYTRUDA can cause type 1 diabetes mellitus, including diabetic
ketoacidosis, which have been reported in 6 (0.2%) of 2799
patients. Monitor patients for hyperglycemia or other signs and
symptoms of diabetes. Administer insulin for type 1 diabetes, and
withhold KEYTRUDA and administer antihyperglycemics in patients
with severe hyperglycemia.
KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred
in 9 (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2
(0.1%), 3 (0.1%), and 4 (<0.1%) nephritis. Monitor patients for
changes in renal function. Administer corticosteroids for Grade 2
or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently
discontinue KEYTRUDA for Grade 3 or 4 nephritis.
KEYTRUDA can cause other clinically important immune-mediated
adverse reactions. For suspected immune-mediated adverse reactions,
ensure adequate evaluation to confirm etiology or exclude other
causes. Based on the severity of the adverse reaction, withhold
KEYTRUDA and administer corticosteroids. Upon improvement to Grade
1 or less, initiate corticosteroid taper and continue to taper over
at least 1 month. Based on limited data from clinical studies in
patients whose immune-related adverse reactions could not be
controlled with corticosteroid use, administration of other
systemic immunosuppressants can be considered. Resume KEYTRUDA when
the adverse reaction remains at Grade 1 or less following
corticosteroid taper. Permanently discontinue KEYTRUDA for any
Grade 3 immune-mediated adverse reaction that recurs and for any
life-threatening immune-mediated adverse reaction.
The following clinically significant immune-mediated adverse
reactions occurred in less than 1% (unless otherwise indicated) of
2799 patients: arthritis (1.5%), exfoliative dermatitis, bullous
pemphigoid, rash (1.4%), uveitis, myositis, Guillain-Barré
syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic
anemia, and partial seizures arising in a patient with inflammatory
foci in brain parenchyma.
KEYTRUDA can cause severe or life-threatening infusion-related
reactions, which have been reported in 6 (0.2%) of 2799 patients.
Monitor patients for signs and symptoms of infusion-related
reactions, including rigors, chills, wheezing, pruritus, flushing,
rash, hypotension, hypoxemia, and fever. For Grade 3 or 4
reactions, stop infusion and permanently discontinue KEYTRUDA.
Based on its mechanism of action, KEYTRUDA can cause fetal harm
when administered to a pregnant woman. If used during pregnancy, or
if the patient becomes pregnant during treatment, apprise the
patient of the potential hazard to a fetus. Advise females of
reproductive potential to use highly effective contraception during
treatment and for 4 months after the last dose of KEYTRUDA
(pembrolizumab).
In KEYNOTE-006, KEYTRUDA was discontinued due to adverse
reactions in 9% of 555 patients with advanced melanoma; adverse
reactions leading to discontinuation in more than one patient were
colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction
(0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). Adverse
reactions leading to interruption of KEYTRUDA occurred in 21% of
patients; the most common (≥1%) was diarrhea (2.5%). The most
common adverse reactions with KEYTRUDA vs ipilimumab were fatigue
(28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs 23%), and
nausea (21% with KEYTRUDA). Corresponding incidence rates are
listed for ipilimumab only for those adverse reactions that
occurred at the same or lower rate than with KEYTRUDA.
In KEYNOTE-002, KEYTRUDA was discontinued due to adverse
reactions in 12% of 357 patients with advanced melanoma; the most
common (≥1%) were general physical health deterioration (1%),
asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized
edema (1%). Adverse reactions leading to interruption of KEYTRUDA
occurred in 14% of patients; the most common (≥1%) were dyspnea
(1%), diarrhea (1%), and maculopapular rash (1%). The most common
adverse reactions with KEYTRUDA vs chemotherapy were fatigue (43%
with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),
constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea
(20% vs 20%), and decreased appetite (20% with KEYTRUDA).
Corresponding incidence rates are listed for chemotherapy only for
those adverse reactions that occurred at the same or lower rate
than with KEYTRUDA.
KEYTRUDA was discontinued due to adverse reactions in 8% of 682
patients with metastatic NSCLC. The most common adverse event
resulting in permanent discontinuation of KEYTRUDA was pneumonitis
(1.8%). Adverse reactions leading to interruption of KEYTRUDA
occurred in 23% of patients; the most common (≥1%) were diarrhea
(1%), fatigue (1.3%), pneumonia (1%), liver enzyme elevation
(1.2%), decreased appetite (1.3%), and pneumonitis (1%). The most
common adverse reactions (occurring in at least 20% of patients and
at a higher incidence than with docetaxel) were decreased appetite
(25% vs 23%), dyspnea (23% vs 20%), and nausea (20% vs 18%).
KEYTRUDA was discontinued due to adverse reactions in 17% of 192
patients with HNSCC. Serious adverse reactions occurred in 45% of
patients. The most frequent serious adverse reactions reported in
at least 2% of patients were pneumonia, dyspnea, confusional state,
vomiting, pleural effusion, and respiratory failure. The most
common adverse reactions (reported in at least 20% of patients)
were fatigue, decreased appetite, and dyspnea. Adverse reactions
occurring in patients with HNSCC were generally similar to those
occurring in patients with melanoma or NSCLC, with the exception of
increased incidences of facial edema (10% all Grades; 2.1% Grades 3
or 4) and new or worsening hypothyroidism.
It is not known whether KEYTRUDA (pembrolizumab) is excreted in
human milk. Because many drugs are excreted in human milk, instruct
women to discontinue nursing during treatment with KEYTRUDA and for
4 months after the final dose.
Safety and effectiveness of KEYTRUDA have not been established
in pediatric patients.
For more information about KEYTRUDA, please see the
Prescribing Information for KEYTRUDA
(pembrolizumab) at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf and
Patient Information/Medication Guide for
KEYTRUDA at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf"
About HALAVEN® (eribulin mesylate)
Injection
HALAVEN® (eribulin mesylate) is a microtubule
dynamics inhibitor indicated for the treatment of patients
with:
- Metastatic breast cancer who have previously received at least
two chemotherapeutic regimens for the treatment of metastatic
disease. Prior therapy should have included an anthracycline and a
taxane in either the adjuvant or metastatic setting.
- Unresectable or metastatic liposarcoma who have received a
prior anthracycline- containing regimen.
Discovered and developed by Eisai, eribulin is a synthetic
analog of halichondrin B, a natural product that was isolated from
the marine sponge Halichondria okadai. First in the
halichondrin class, Halaven is a microtubule dynamics inhibitor.
Eribulin is believed to work primarily via a tubulin-based
mechanism that causes prolonged and irreversible mitotic blockage,
ultimately leading to apoptotic cell death. Additionally, in
preclinical studies of human breast cancer, eribulin demonstrated
complex effects on the tumor biology of surviving cancer cells,
including increases in vascular perfusion resulting in reduced
tumor hypoxia, and changes in the expression of genes in tumor
specimens associated with a change in phenotype, promoting the
epithelial phenotype, opposing the mesenchymal phenotype. Eribulin
has also been shown to decrease the migration and invasiveness of
human breast cancer cells.
Important Safety Information for Halaven (eribulin mesylate)
Injection
Warnings and Precautions
Neutropenia: Severe neutropenia (ANC
<500/mm3) lasting >1 week occurred in 12% of
patients with mBC and liposarcoma or leiomyosarcoma. Febrile
neutropenia occurred in 5% of patients with mBC and 2 patients
(0.4%) died from complications. Febrile neutropenia occurred in
0.9% of patients with liposarcoma or leiomyosarcoma, and fatal
neutropenic sepsis occurred in 0.9% of patients. Patients with mBC
with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN
experienced a higher incidence of Grade 4 neutropenia and febrile
neutropenia than patients with normal levels. Monitor complete
blood cell counts prior to each dose, and increase the frequency of
monitoring in patients who develop Grade 3 or 4 cytopenias. Delay
administration and reduce subsequent doses in patients who
experience febrile neutropenia or Grade 4 neutropenia lasting >7
days.
Peripheral Neuropathy: Grade 3 peripheral neuropathy
occurred in 8% of patients with mBC (Grade 4=0.4%) and 22%
developed a new or worsening neuropathy that had not recovered
within a median follow-up duration of 269 days (range 25-662 days).
Neuropathy lasting >1 year occurred in 5% of patients with mBC.
Grade 3 peripheral neuropathy occurred in 3.1% of patients with
liposarcoma and leiomyosarcoma receiving Halaven and neuropathy
lasting more than 60 days occurred in 58% (38/65) of patients who
had neuropathy at the last treatment visit. Patients should be
monitored for signs of peripheral motor and sensory neuropathy.
Withhold Halaven in patients who experience Grade 3 or 4 peripheral
neuropathy until resolution to Grade 2 or less.
Embryo-Fetal Toxicity: Halaven can cause fetal harm when
administered to a pregnant woman. Advise females of reproductive
potential to use effective contraception during treatment with
Halaven and for at least 2 weeks following the final dose. Advise
males with female partners of reproductive potential to use
effective contraception during treatment with Halaven and for 3.5
months following the final dose.
QT Prolongation: Monitor for prolonged QT intervals in
patients with congestive heart failure, bradyarrhythmias, drugs
known to prolong the QT interval, and electrolyte abnormalities.
Correct hypokalemia or hypomagnesemia prior to initiating Halaven
and monitor these electrolytes periodically during therapy. Avoid
in patients with congenital long QT syndrome.
Adverse Reactions
In patients with mBC receiving Halaven (eribulin mesylate)
Injection, the most common adverse reactions (≥25%) were
neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia
(45%), peripheral neuropathy (35%), nausea (35%), and constipation
(25%). Febrile neutropenia (4%) and neutropenia (2%) were the most
common serious adverse reactions. The most common adverse reaction
resulting in discontinuation was peripheral neuropathy (5%).
In patients with liposarcoma and leiomyosarcoma receiving
Halaven, the most common adverse reactions (≥25%) reported in
patients receiving Halaven were fatigue (62%), nausea (41%),
alopecia (35%), constipation (32%), peripheral neuropathy (29%),
abdominal pain (29%), and pyrexia (28%). The most common (≥5%)
Grade 3-4 laboratory abnormalities reported in patients receiving
Halaven were neutropenia (32%), hypokalemia (5.4%), and
hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the
most common serious adverse reactions. The most common adverse
reactions resulting in discontinuation were fatigue and
thrombocytopenia (0.9% each).
Use in Specific Populations
Lactation: Because of the potential for serious adverse
reactions in breastfed infants from eribulin mesylate, advise women
not to breastfeed during treatment with Halaven and for 2 weeks
after the final dose.
Hepatic and Renal Impairment: A reduction in starting
dose is recommended for patients with mild or moderate hepatic
impairment and/or moderate or severe renal impairment.
For more information about Halaven, click here for the full
Prescribing Information.
Merck's Focus on Cancer
Merck's goal is to translate breakthrough science into
innovative oncology medicines to help people with cancer worldwide.
At Merck, helping people fight cancer is our passion and supporting
accessibility to our cancer medicines is our commitment. Our focus
is on pursuing research in immuno-oncology and we are accelerating
every step in the journey – from lab to clinic – to potentially
bring new hope to people with cancer.
As part of our focus on cancer, Merck is committed to exploring
the potential of immuno-oncology with one of the fastest-growing
development programs in the industry. We are currently executing an
expansive research program that includes nearly 400 clinical trials
evaluating our anti-PD-1 therapy across more than 30 tumor types.
We also continue to strengthen our immuno-oncology portfolio
through strategic acquisitions and are prioritizing the development
of several promising immunotherapeutic candidates with the
potential to improve the treatment of advanced cancers.
For more information about our oncology clinical trials, visit
www.merck.com/clinicaltrials.
About Merck
For 125 years, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies, and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, YouTube and
LinkedIn.
About Eisai Inc.
At Eisai Inc., human health care (hhc) is our
goal. We give our first thought to patients and their families, and
helping to increase the benefits health care provides. As the U.S.
pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a
passionate commitment to patient care that is the driving force
behind our efforts to discover and develop innovative therapies to
help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that
operates in two global business groups: oncology and neurology
(dementia-related diseases and neurodegenerative diseases). Each
group functions as an end-to-end global business with discovery,
development, and marketing capabilities. Our U.S. headquarters,
commercial and clinical development organizations are located in
New Jersey; our discovery labs are
in Massachusetts and Pennsylvania; and our global demand chain
organization resides in Maryland
and North Carolina. To learn more
about Eisai Inc., please visit us at www.eisai.com/US.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes
"forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These statements are based upon the current beliefs and
expectations of the company's management and are subject to
significant risks and uncertainties. There can be no guarantees
with respect to pipeline products that the products will receive
the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate
or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States
and internationally; global trends toward health care cost
containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; the company's
ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of the company's patents and other protections for
innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company's 2015
Annual Report on Form 10-K and the company's other filings with the
Securities and Exchange Commission (SEC) available at the SEC's
Internet site (www.sec.gov).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/interim-results-from-phase-1b2-study-evaluating-the-combination-of-mercks-keytruda-pembrolizumab-and-eisais-halaven-eribulin-mesylate-injection-in-metastatic-triple-negative-breast-cancer-presented-at-2016-san-antonio-bre-300376391.html
SOURCE Eisai Inc.